SG11201907443PA - Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders - Google Patents

Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders

Info

Publication number
SG11201907443PA
SG11201907443PA SG11201907443PA SG11201907443PA SG11201907443PA SG 11201907443P A SG11201907443P A SG 11201907443PA SG 11201907443P A SG11201907443P A SG 11201907443PA SG 11201907443P A SG11201907443P A SG 11201907443PA SG 11201907443P A SG11201907443P A SG 11201907443PA
Authority
SG
Singapore
Prior art keywords
taipei
chien
dist
nei
kang
Prior art date
Application number
SG11201907443PA
Inventor
Po-Yuan Tseng
Wei-Shu Lu
Carl Brown
I-Yin Lin
Chen-En Tsai
Chih-Kuang Chen
Original Assignee
Twi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twi Biotechnology Inc filed Critical Twi Biotechnology Inc
Publication of SG11201907443PA publication Critical patent/SG11201907443PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

450 400 350 300 • 250 200 ;2 150 106 50 0. Fig, 18: -4- 4 4= , 2 7 1- 7 O 11 , 8 7- C.7 as) 1. 5 I CJ CJ C.> CeD a.* at. CID fah COD (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) WIP0 I PCT omit VIII °nolo 1101 IIII iflo oimIE (10) International Publication Number WO 2018/136706 Al (51) International Patent Classification: A61K 31/43 75 (2006.01) A61P 17/18 (2006.01) A61K 31/4745 (2006.01) (21) International Application Number: PCT/US2018/014366 (22) International Filing Date: 19 January 2018 (19.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/448,219 19 January 2017 (19.01.2017) US (71) Applicant: TWI BIOTECHNOLOGY, INC.; 8F, No.41 Lane 221, Kang Chien Rd., Nei Hu Dist., Taipei, 114 (TW). (72) Inventor; and (71) Applicant US only): BROWN, Carl, Oscar [US/US]; 13034 Alora Point, San Diego, CA 92130 (US). (72) Inventors: TSENG, Po-yuan; 8F, No.41 Lane 221, Kang Chien Rd., Nei Hu Dist., Taipei, 114 (TW). LU, Wei-shu; 8F, No.41 Lane 221, Kang Chien Rd., Nei Hu Dist., Taipei, 114 (TW). LIN, I-yin; 8F, No.41 Lane 221, Kang Chien Rd., Nei Hu Dist., Taipei, 114 (TW). TSAI, Chen-en; 8F, No.41 Lane 221, Kang Chien Rd., Nei Hu Dist., Taipei, 114 (TW). CHEN, Chih-kuang; 8F, No.41 Lane 221, Kang Chien Rd., Nei Hu Dist., Taipei, 114 (TW). (74) Agent: POLYAKOV, Mark, V et al.; Wood, Phillips, Katz, Clark & Mortimer, 500 West Madison Street, Suite 1130, Chicago, IL 60661 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING IMMUNOINFLAM- = MATORY DERMAL DISORDERS (57) : A method for preventing or treating immunoinflammatory dermal disorders is provided. Also provided is a pharmaceu- tical composition for preventing or treating immunoinflammatory dermal disorders N O N C
SG11201907443PA 2017-01-19 2018-01-19 Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders SG11201907443PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762448219P 2017-01-19 2017-01-19
PCT/US2018/014366 WO2018136706A1 (en) 2017-01-19 2018-01-19 Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders

Publications (1)

Publication Number Publication Date
SG11201907443PA true SG11201907443PA (en) 2019-09-27

Family

ID=62838768

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907443PA SG11201907443PA (en) 2017-01-19 2018-01-19 Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders

Country Status (9)

Country Link
US (1) US10675260B2 (en)
EP (1) EP3570835B1 (en)
JP (2) JP2020505362A (en)
KR (1) KR102563841B1 (en)
CN (2) CN116919957A (en)
CA (1) CA3049450A1 (en)
SG (1) SG11201907443PA (en)
TW (1) TWI794200B (en)
WO (1) WO2018136706A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6535146B1 (en) * 2019-03-08 2019-06-26 佐藤製薬株式会社 Skin barrier function improver
CN112679492B (en) * 2019-10-17 2022-03-18 中国科学院上海药物研究所 Berberine derivative, preparation method and application thereof
CN112538081A (en) * 2020-12-15 2021-03-23 辽宁中医药大学 Palmatine derived from cortex Phellodendri salt-roasted product, and its separation and preparation method and application
CN114236132B (en) * 2021-11-26 2024-02-02 李小光 ELISA kit for detecting human BP180IgG antibody and application thereof
CN117257799A (en) * 2023-11-03 2023-12-22 云南中医药大学 Application of palmatine in preparation of medicine for treating urticaria

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR026801A1 (en) * 2000-01-12 2003-02-26 Medidom Lab SUBSTANCES FOR USE IN THE TREATMENT OF PSORIASIS
US6610750B1 (en) * 2000-09-15 2003-08-26 Laboratoires Negma Treatment of osteoarthritis
CN100586428C (en) * 2001-11-02 2010-02-03 加州大学校务委员会 Compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection and application thereof in preparing medicine
KR20030082200A (en) * 2002-04-17 2003-10-22 주식회사 엘지생활건강 Composition for preventing and alleviating atopic dermatitis containing berberine
FR2842738B1 (en) * 2002-07-23 2006-02-10 Negma Lerads USE OF A RHEINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF CHRONIC INFLAMMATION, THE PREVENTION AND TREATMENT OF REJECTION OF ORGAN AND TISSUE TRANSPLANTATION
TW200533369A (en) * 2004-03-10 2005-10-16 Pepgen Corp Applications of treatment using interferon-tau
AU2005247403A1 (en) * 2004-05-17 2005-12-08 Combinatorx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders
CN100441183C (en) * 2005-08-29 2008-12-10 中国医学科学院皮肤病研究所 Use of chloride 13-hexyl berberine and chloride 13-hexyl palmatine in preparation of medicine for treating moist tetter, dermatitis and psoriasis
TWI473610B (en) * 2008-10-28 2015-02-21 Twi Biotechnology Inc Pharmaceutical compositions containing diacerein
KR20170116231A (en) * 2009-06-30 2017-10-18 더만 바이오메디슨 코. 엘티디. Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders
WO2012160188A1 (en) * 2011-05-26 2012-11-29 Jado Technologies Gmbh Hydroxy-substituted amino and ammonium derivatives and their medical use
US20140243354A1 (en) * 2013-02-22 2014-08-28 Galderma Research & Development Snc Combinations of indigo naturalis and berberine and uses thereof
TW201538156A (en) * 2013-12-19 2015-10-16 Twi Biotechnology Inc Berberine formulations and uses thereof
KR102275267B1 (en) * 2014-01-25 2021-07-09 주식회사 엘지생활건강 Composition for improving skin
CN103919777A (en) * 2014-05-04 2014-07-16 杨献华 Medicinal composition for preventing and treating psoriasis and application thereof
EP3313520A4 (en) * 2015-06-24 2019-01-02 TWI Biotechnology, Inc. Therapeutic uses of berberine formulations
CN117482078A (en) * 2015-07-01 2024-02-02 安成生物科技股份有限公司 Topical formulations of diacerein or rhein and uses thereof

Also Published As

Publication number Publication date
CN110191710A (en) 2019-08-30
US20180200235A1 (en) 2018-07-19
JP2020505362A (en) 2020-02-20
CN110191710B (en) 2023-04-18
KR20190105070A (en) 2019-09-11
WO2018136706A1 (en) 2018-07-26
KR102563841B1 (en) 2023-08-03
EP3570835B1 (en) 2023-08-09
JP2022078204A (en) 2022-05-24
US10675260B2 (en) 2020-06-09
CN116919957A (en) 2023-10-24
EP3570835A4 (en) 2021-03-03
TWI794200B (en) 2023-03-01
EP3570835A1 (en) 2019-11-27
TW201831474A (en) 2018-09-01
JP7381629B2 (en) 2023-11-15
CA3049450A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
SG11201907443PA (en) Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201808990QA (en) Compositions for topical application of compounds
SG11201810210UA (en) Engineered botulinum neurotoxins
SG11201810327XA (en) Single domain serum albumin binding protein
SG11201805137XA (en) Virus encoding an anti-tcr-complex antibody or fragment
SG11201907032RA (en) Amino pyrimidine compounds useful as ssao inhibitors
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11202000312UA (en) Encapsulated polynucleotides and methods of use
SG11201901347UA (en) Compositions and methods for cancer immunotherapy
SG11201809594WA (en) Nicotine particles and compositions
SG11201903889TA (en) Crenolanib for treating flt3 mutated proliferative disorders associated mutations
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201804721SA (en) Modulators of complement activity
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases